Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in budd-chiari syndrome and their impact on thrombotic complications post Liver Transplantation

Institute of Liver Studies, King's College Hospital, National Health Service Foundation Trust, London, United Kingdom.
Liver Transplantation (Impact Factor: 4.24). 07/2012; 18(7):819-27. DOI: 10.1002/lt.23443
Source: PubMed


Latent myeloproliferative disorders (MPDs) can be identified by Janus kinase 2 (JAK2) mutations in patients with idiopathic Budd-Chiari syndrome (BCS). The incidence and clinical outcomes of JAK2 mutations, novel ten-eleven translocation 2 (TET2) mutations, and the 46/1 haplotype in BCS are unknown for liver transplantation (LT). We undertook molecular studies of 66 patients presenting with BCS and correlated the results with the clinical outcomes. An overt MPD was present in 20% of the cases, and a latent MPD confirmed by the presence of a JAK2 mutation was detected in 45%. Testing for a TET2 mutation identified MPDs at the molecular level in another 7% of the subset of patients with BCS who were evaluated. The 46/1 haplotype frequency was significantly greater in BCS patients versus the general population (P < 0.001). The presence of JAK2 and TET2 mutations had no impact on 1-year survival. Thirty-six patients underwent LT, and 12 developed liver-related thrombotic complications (33%). Ten of these 12 patients required retransplantation. Retransplantation was more likely in those patients who developed liver-related thrombotic complications (P < 0.001). A JAK2 mutation was highly associated with the development of thrombotic complications after LT (P = 0.005). In conclusion, the presence of JAK2V617F predicts hepatic and extrahepatic thrombotic complications after LT. Testing for TET2 mutations can identify another 7% of idiopathic BCS patients with molecular MPDs.

Download full-text


Available from: Nicholas Charles Lea, Dec 15, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: A recurrent JAK2V617F mutation is typically associated with chronic myeloproliferative neoplasms (MPNs) that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis. This mutation results in a gain of function that is credited to underlie most of the pathogenesis and phenotypic characteristics of these disorders; it serves as a key diagnostic marker and represents a suitable target for JAK2 inhibitors. Because cardiovascular events represent the main cause of morbidity and mortality in PV and ET, current patients' risk stratification is based on variables predicting individual thrombotic risk (age and previous thrombotic history). However, evidence is accumulating that supports a role of JAK2V617F mutation as a novel risk factor for thrombosis, although prospective validation has not been provided yet. In this review, we discuss about potential mechanisms that link mutated JAK2 with the thrombotic propensity of MPN and the clinical correlates; hopefully, novel information could result in better patient management.
    Seminars in Thrombosis and Hemostasis 04/2013; 39(5). DOI:10.1055/s-0033-1343890 · 3.88 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Splanchnic vein thrombosis (SVT) is one of the most important complications of myeloproliferative neoplasms (MPN). Although MPN are common causes of SVT, the pathophysiological mechanisms underlying this predisposition, their epidemiology and natural history are not fully understood. Studies have concentrated on the generalized prothrombotic environment generated by MPN and their relationship with abnormal blood counts, thereby furthering our knowledge of arterial and venous thrombosis in this population. In contrast, there are few studies that have specifically addressed SVT in the context of MPN. Recent research has demonstrated in patients with MPN the existence of factors increasing the risk of SVT such as the presence of the JAK2 V617F mutation and its 46/1 haplotype. Features unique to the circulating blood cells, splanchnic vasculature and surrounding micro-environment in patients with MPN have been described. There are also abnormalities in local haemodynamics, haemostatic molecules, the spleen, and splanchnic endothelial and endothelial progenitor cells. This review considers these important advances and discusses the contribution of individual anomalies that lead to the development of SVT in both the pre-neoplastic and overt stage of MPN. Clinical issues relating to epidemiology, recurrence and survival in these patients have also been reviewed and their results discussed.
    British Journal of Haematology 07/2013; 162(6). DOI:10.1111/bjh.12461 · 4.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction: The Budd–Chiari Syndrome (BCS) is a rare and life-threatening disorder caused by the obstruction of hepatic venous outflow. The clinical presentation of BCS can range from the absence of symptoms to the development of end-stage liver disease or fulminant liver failure. Areas covered: This review provides an overview of the available treatments for BCS. Long-term anticoagulation is mandatory in all patients with BCS. The need for an additional intervention, such as hepatic vein angioplasty, thrombolysis, transjugular intrahepatic portosystemic shunt, surgical shunts or liver transplantation depends on the severity of symptoms and response to treatment. Due to the low prevalence of the disease, knowledge of management of BCS is mostly based on retrospective series and expert opinion and hampered the development of randomized controlled trials. Expert opinion: Outcome of BCS has improved in the last decades, mainly due to the increased suspicion and early treatment instauration; the frequent recognition of an underlying systemic prothrombotic disorder and its ensuing adequate treatment; the widespread use of long-term anticoagulation and the implementation of a stepwise management strategy based on the clinical response to the previous step of treatment. Further studies are needed to better define treatment failure and the optimal timing for scaling in treatment.
    Expert Opinion on Orphan Drugs 01/2014; 2(2). DOI:10.1517/21678707.2014.872560 · 0.53 Impact Factor
Show more